A carregar...
Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
BACKGROUND: The CheckMate 141 trial found that nivolumab improved survival for patients with recurrent or metastatic head and neck cancer (HNC). Despite the improved survival, nivolumab is much more expensive than standard therapies. This study assesses the cost-effectiveness of nivolumab for the tr...
Na minha lista:
| Publicado no: | J Natl Cancer Inst |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5946900/ https://ncbi.nlm.nih.gov/pubmed/29126314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djx226 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|